Landscape of Biomarker Testing for NSCLC
By
Springer Healthcare IME
FEATURING
Fernando López-Ríos
By
Springer Healthcare IME
FEATURING
Fernando López-Ríos
Fernando Lopez-Rios outlines current biomarkers that should be tested for in non-small cell lung cancer (NSCLC), the current landscape of biomarker testing, and clinical practice gaps.
View our CME-accredited clinical pathway tool, designed to guide you through the best practices for detection and treatment of NTRK fusions in NSCLC at https://nsclc-biomarkers-ime.springermedicine.com/courses/detecting-and-targeting-ntrk-fusions-in-nsclc/
This tool is summarised into a free, downloadable practice aid available for use directly in your clinical practice. Complete the short evaluation form available on the page to collect your CME credits.
This independent medical education program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
View our CME-accredited clinical pathway tool, designed to guide you through the best practices for detection and treatment of NTRK fusions in NSCLC at https://nsclc-biomarkers-ime.springermedicine.com/courses/detecting-and-targeting-ntrk-fusions-in-nsclc/
This tool is summarised into a free, downloadable practice aid available for use directly in your clinical practice. Complete the short evaluation form available on the page to collect your CME credits.
This independent medical education program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Comments 0
Login to view comments.
Click here to Login
